Key facts
- This page summarizes Richard I. Eisenstadt's Form 4 filing for Altimmune, Inc. (ALT).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 29 Jan 2024, 18:30.
Richard I. Eisenstadt - 25 Jan 2024 Form 4 Insider Report for Altimmune, Inc. (ALT)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ALT
- Reported as of
- 25 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Jan 2024, 18:30:13 UTC
- Prior SEC filing
- 02 Jan 2024
- Next SEC filing
- 01 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Richard Eisenstadt
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Richard I. Eisenstadt filed Form 4 for Altimmune, Inc. (ALT) on 29 Jan 2024.
Change
- Previous filing in this sequence was filed on 02 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ALT
transaction
Derivative
Stock Options (option to buy)
Award
- Transaction value
- $0
- Shares
- +163,200
- Change %
- Price
- $0.000000
- Shares after
- 163,200
- Date
- 25 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.0001
- Underlying amount
- 163,200
- Exercise price
- $9.28
- Footnotes
- F1
ALT
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +58,400
- Change %
- Price
- $0.000000
- Shares after
- 58,400
- Date
- 25 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.0001
- Underlying amount
- 58,400
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Twenty-five percent of the shares underlying the option become vested and exercisable on January 25, 2025 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 25, 2025, subject to the reporting person's continued service through the applicable vesting date.
Footnote F2
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
Footnote F3
The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.